Latest news with #AntoinePapiernik
Yahoo
2 days ago
- Business
- Yahoo
Sofinnova taps NVIDIA to bolster portfolio companies' computational power
Sofinnova Partners has partnered with NVIDIA in a move intended to equip its life sciences portfolio companies with faster processing speeds for processing complex biological datasets. The French VC said that amid increasing demand for computational resources driven by artificial intelligence (AI), its portfolio companies will now be able to access NVIDIA Blackwell and related graphical processing units (GPU) offered by the technology giant via NVIDIA DGX Cloud Lepton, an AI platform and marketplace that connects developers to global AI infrastructure. According to a report by GlobalData, the global revenue for AI platforms across healthcare is forecast to reach $18.8bn by 2027. Sofinnova's most recent fund is focused on digital medicine. By partnering with Nvidia, its portfolio companies in the area, including startups BioCorteX, Bioptimus, and Cure51, will be to process biological datasets and run computational models to complete tasks 'within days' that would previously have taken months through Cloud Lepton, the VC said. Sofinnova Partners' chairman and managing partner Antoine Papiernik commented: "This collaboration supercharges computation for life sciences innovation. The convergence of biology, AI, computation, and data isn't just our investment thesis – it's the defining battleground of the next decade. 'By securing access to Nvidia's infrastructure, we're not just funding companies; we're empowering them with the computational backbone needed to outperform incumbents and redefine what's possible in drug discovery, precision medicine, and scalable solutions that address both human health and sustainability." In March, Sofinnova's life sciences fund reached €4bn ($4.6bn). Papiernik said that following the milestone, the VC plans to invest in 50 to 60 new companies, adding to the more than 100 life sciences companies it has invested in to date, including the cardiovascular medtech company Shockwave Medical. Sofinnova also has Sofinnova AI. Launched in 2023 and combining data analytics and machine learning, the VC has stated that this fund is intended to strengthen its ability to identify innovations and accelerate the development of life sciences companies. News of the partnership coincides with Nvidia's GTC conference, taking place in Paris, France from 10-12 June. During a presentation at the event, Nvidia CEO Jensen Huang said: 'Europe isn't just adopting AI — it's building it.' Notable healthcare announcements at the event included a new collaboration between Nvidia and Novo Nordisk to accelerate drug discovery efforts through AI use cases, with Nvidia's aim to create customised AI models and agents that Novo Nordisk can use ind early research and clinical development. Nvidia also announced a new partnership with GE HealthCare intended to advance innovation in autonomous imaging with a focus on developing autonomous X-ray technologies and ultrasound applications. "Sofinnova taps NVIDIA to bolster portfolio companies' computational power" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 days ago
- Business
- Business Wire
Sofinnova Partners Collaborates With NVIDIA to Accelerate European Life Sciences Startups
PARIS--(BUSINESS WIRE)-- Sofinnova Partners ('Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced a collaboration with NVIDIA to support its portfolio of life sciences startups. The collaboration delivers significant Graphics Processing Unit (GPU) credits to select Sofinnova portfolio companies, effectively giving access to the same computational firepower used by tech titans in Silicon Valley. Amidst increasing demand for computational resources driven by AI, Sofinnova's portfolio companies will be able to access NVIDIA Blackwell and other NVIDIA architecture GPUs via NVIDIA DGX Cloud Lepton, an AI platform and marketplace connecting developers to global AI infrastructure. BioCorteX, Bioptimus, Cure51 and Latent Labs —four of Europe's most promising digital medicine startups—will gain access to computing resources through DGX Cloud Lepton, enabling them to process biological data sets and run computational models that would have taken months, completing them in days. Cure51, a pioneer in decoding the biology of exceptional cancer survivors, tested NVIDIA Parabricks, a GPU-accelerated genomics toolkit, and achieved up to 17x faster processing with NVIDIA H100 GPUs and more than 2x cost savings with NVIDIA L4 GPUs compared to their CPU baseline—dramatically accelerating their ability to analyze complex genomic data and scale their survivor-based insights. "This collaboration supercharges computation for life sciences innovation," said Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners. "The convergence of biology, AI, computation, and data isn't just our investment thesis—it's the defining battleground of the next decade. From our Digital Medicine strategy to our own proprietary AI platform we recognize the transformative potential of AI across our entire domain. By securing access to NVIDIA's infrastructure, we're not just funding companies; we're empowering them with the computational backbone needed to outperform incumbents and redefine what's possible in drug discovery, precision medicine, and scalable solutions that address both human health and sustainability." Learn more about NVIDIA DGX Cloud Lepton and view the official NVIDIA announcement. ### About Sofinnova Partners Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit:
